| Chemical sulfation of small molecules—Advances and challenges RA Al-Horani, UR Desai Tetrahedron 66 (16), 2907-2918, 2010 | 219 | 2010 |
| Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa RA Al-Horani, P Ponnusamy, AY Mehta, D Gailani, UR Desai Journal of medicinal chemistry 56 (3), 867-878, 2013 | 92 | 2013 |
| Recent advances on plasmin inhibitors for the treatment of fibrinolysis‐related disorders RA Al‐Horani, UR Desai Medicinal research reviews 34 (6), 1168-1216, 2014 | 88 | 2014 |
| Factor XIa inhibitors: a review of the patent literature RA Al-Horani, UR Desai Expert opinion on therapeutic patents 26 (3), 323-345, 2016 | 77 | 2016 |
| Recent advances in the discovery and development of factor XI/XIa inhibitors RA Al‐Horani, DK Afosah Medicinal research reviews 38 (6), 1974-2023, 2018 | 67 | 2018 |
| Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials RA Al-Horani, S Kar, KF Aliter International Journal of Molecular Sciences 21 (15), 5224, 2020 | 65 | 2020 |
| Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides RA Al-Horani, UR Desai Journal of Medicinal Chemistry 57 (11), 4805-4818, 2014 | 62 | 2014 |
| Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site R Karuturi, RA Al-Horani, SC Mehta, D Gailani, UR Desai Journal of medicinal chemistry 56 (6), 2415-2428, 2013 | 54 | 2013 |
| Designing nonsaccharide, allosteric activators of antithrombin for accelerated inhibition of factor Xa RA Al-Horani, A Liang, UR Desai Journal of medicinal chemistry 54 (17), 6125-6138, 2011 | 49 | 2011 |
| Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: A comprehensive review RA Al-Horani, S Kar Viruses 12 (10), 1092, 2020 | 48 | 2020 |
| Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19 KF Aliter, RA Al-Horani Cardiovascular Drugs and Therapy 35, 195-203, 2021 | 45 | 2021 |
| Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants RA Al-Horani, D Gailani, UR Desai Thrombosis research 136 (2), 379-387, 2015 | 43 | 2015 |
| Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells NJ Patel, R Karuturi, RA Al-Horani, S Baranwal, J Patel, UR Desai, ... ACS chemical biology 9 (8), 1826-1833, 2014 | 43 | 2014 |
| Allosteric partial inhibition of monomeric proteases. Sulfated coumarins induce regulation, not just inhibition, of thrombin S Verespy III, AY Mehta, D Afosah, RA Al-Horani, UR Desai Scientific Reports 6 (1), 24043, 2016 | 40 | 2016 |
| Factor XI (a) inhibitors for thrombosis: an updated patent review (2016-present) RA Al-Horani Expert opinion on therapeutic patents 30 (1), 39-55, 2020 | 37 | 2020 |
| Serpin regulation of fibrinolytic system: implications for therapeutic applications in cardiovascular diseases R A Al-Horani Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly …, 2014 | 33 | 2014 |
| Potent, selective, allosteric inhibition of human plasmin by sulfated non-saccharide glycosaminoglycan mimetics DK Afosah, RA Al-Horani, NV Sankaranarayanan, UR Desai Journal of medicinal chemistry 60 (2), 641-657, 2017 | 31 | 2017 |
| Potential therapeutic roles for direct factor Xa inhibitors in coronavirus infections RA Al-Horani American Journal of Cardiovascular Drugs 20 (6), 525-533, 2020 | 30 | 2020 |
| Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold RA Al-Horani, AY Mehta, UR Desai European journal of medicinal chemistry 54, 771-783, 2012 | 29 | 2012 |
| Electronically rich N-substituted tetrahydroisoquinoline 3-carboxylic acid esters: concise synthesis and conformational studies RA Al-Horani, UR Desai Tetrahedron 68 (8), 2027-2040, 2012 | 29 | 2012 |
